Desloratadine/pseudoephedrine
| Combination of | |
|---|---|
| Desloratadine | Antihistamine |
| Pseudoephedrine | Decongestant |
| Clinical data | |
| Trade names | Clarinex-D, Aerinaze |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Desloratadine/pseudoephedrine, sold under the brand name Clarinex-D among others, is a
Desloratadine/pseudoephedrine was approved for use in the United States in 2005[1][3] and in the European Union in July 2007.[2]
Medical uses
Desloratadine/pseudoephedrine is
indicated for the symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion.[2]
References
- ^ a b c "Clarinex-D 12 Hour- desloratadine and pseudoephedrine sulfate tablet, extended release". DailyMed. 15 March 2019. Retrieved 1 March 2020.
- ^ a b c d "Aerinaze EPAR". European Medicines Agency. Retrieved 1 March 2020.
- ^ "Drug Approval Package: Clarinex-D 24 Hour (Desloratadine/Pseudoephedrine Sulfate) NDA #021605". U.S. Food and Drug Administration (FDA). 9 May 2007. Retrieved 1 March 2020.
Further reading
- Anolik R (June 2009). "Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion". Expert Opin Drug Metab Toxicol. 5 (6): 683–94. S2CID 22633518.
External links
- "Desloratadine mixture with pseudoephedrine". Drug Information Portal. U.S. National Library of Medicine.